Why the study?
No specific antiviral treatments exist for Enterovirus-71-associated neurological disease, and the effect of plasma exchange in these infections is unknown.
Does plasma exchange improve clinical outcomes in patients with severe Enterovirus-71 neurological disease?
Does plasma exchange improve clinical outcomes in patients with severe Enterovirus-71 neurological disease?
Plasma exchange may be an effective complementary therapy for severe Enterovirus-71 neurological disease.
Answers are grounded in this paper and cite their sources.
Plasma exchange may benefit severe EV71 neurological disease; leaves open efficacy pending controlled trials.
The clinical spectrum of Enterovirus-71-associated neurological disease includes acute flaccid paralysis, encephalomyelitis, or brainstem encephalitis with autonomic dysfunction. As no specific antiviral treatments are available, intravenous human immunoglobulin is used in early stages of the illness, decreasing serum proinflammatory cytokines, and improving clinical outcomes. Plasma exchange aims to eliminate pathogenic autoantibodies and proinflammatory cytokines, and is used in diverse immune-mediated neurologic conditions. However, its effect in Enterovirus-71 infections is unknown. We report three cases of severe Enterovirus-71 neurological disease treated with plasma exchange during an outbreak in Catalonia (Spain) in 2016. We observed a striking improvement in all three patients within 48 h of starting plasma exchange. Patients received four to six sessions every other day. Good outcomes were confirmed at the 1-year follow-up visit. Our observations suggest that plasma exchange is an effective complementary therapy for severe Enterovirus-71 neurological disease.
No takes yet. Share an insight, caveat, or question.
Pascual‐Goñi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: